Patent Assignment
Reel/Frame 073832/0312
Assignment of Assignor's Interest
Recorded: 2025-12-03
Pages: 25
Assignor
ESSENTIALIS, INC.
Executed: 2025-11-25
Assignee
SOLENO THERAPEUTICS, INC.
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CALIFORNIA, 94065
Covered Properties
(51)
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
PCT:
PCT/US2005/030481 ↗
Salts of Pottassium Atp Channel Openers and Uses Thereof
PCT:
PCT/US2006/048711 ↗
Salts of Potassium Atp Channel Openers and Uses Thereof
PCT:
PCT/US2008/068936 ↗
Salts of Potassium Atp Channel Openers and Uses Thereof
PCT:
PCT/US2013/027676 ↗
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
PCT:
PCT/US2015/060455 ↗
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
Application:
11/212,130 →
Publication:
US 2006/0051418
Salts of Potassium Atp Channel Openers and Uses Thereof
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
12/166,251 →
Publication:
US 2009/0062264
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
Application:
12/368,215 →
Publication:
US 2009/0149451
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
Application:
12/370,456 →
Publication:
US 2009/0148525
Salts of Potassium Atp Channel Openers and Uses Thereof
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
12/534,018 →
Publication:
US 2010/0028429
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
12/819,155 →
Publication:
US 2010/0256360
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
13/406,482 →
Publication:
US 2012/0238554
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
13/543,665 →
Publication:
US 2013/0040942
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
13/671,418 →
Publication:
US 2013/0309301
Salts of Potassium Atp Channel Openers and Uses Thereof
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
Salts of Potassium Atp Channel Openers and Uses Thereof
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Salts of Potassium Atp Channel Openers and Uses Thereof
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
Application:
15/683,516 →
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
Application:
15/937,594 →
Publication:
US 2018/0280405
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
16/110,621 →
Publication:
US 2019/0117665
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Salts of Potassium Atp Channel Openers and Uses Thereof
Pharmaceutical Formulations of Potassium Atp Channel Openers and Uses Thereof
Application:
16/692,852 →
Publication:
US 2020/0237772
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Application:
17/104,433 →
Publication:
US 2021/0322434
Salts of Potassium Atp Channel Openers and Uses Thereof
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
18/454,595 →
Publication:
US 2024/0252507
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Methods for Treating Subjects with Prader-Willi Syndrome
Use of diazoxide or its derivatives in the treatment of obesity and other diseases of humans and animals
Application:
60/604,085 →
Therapeutic outcomes from the use of diazoxide or its derivatives in the treatment of obesity and other diseases of human and animals
Application:
60/624,219 →
Use of diazoxide or its derivatives and co-formulations in the treatment of obesity and other diseases of humans
Application:
60/654,571 →
Controlled release formulations and co-formulations of diazoxide and derivatives thereof with improved bioavailability, safety and therapeutic efficacy
Application:
60/668,912 →
Salts of potassium ATP channel openers and uses thereof
Application:
60/756,941 →
Salts of potassium ATP channel openers and uses thereof
Application:
60/854,740 →
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
60/947,628 →
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
60/949,207 →
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
60/950,854 →
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
60/986,251 →
Salts of Potassium Atp Channel Openers and Uses Thereof
Application:
61/603,923 →
Methods to Increase Lean Body Mass in Subjects with Prader-Willi Syndrome
Application:
62/080,150 →
Methods to Increase Lean Body Mass in Subjects with Prader-Willi Syndrome
Application:
62/138,245 →
Methods to Increase Lean Body Mass in Subjects with Prader-Willi Syndrome
Application:
62/170,035 →
Methods for Treating Subjects with Prader-Willi Syndrome or Smith-Magenis Syndrome
Application:
62/221,359 →
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Nov 14, 2005
From: COWEN, NEIL MADISON; KASHKIN, KENNETH B.
To: ESSENTIALIS, INC.
Reel/Frame 017011/0734 →
Assignment of Assignor's Interest
Apr 25, 2007
From: COWEN, NEIL M; KASHKIN, KENNETH B; YAMOUT, KHALED A
To: ESSENTIALIS, INC.
Reel/Frame 019211/0197 →
Assignment of Assignor's Interest
Nov 17, 2008
From: COWEN, NEIL M.; DUKES, IAIN
To: ESSENTIALIS, INC.
Reel/Frame 021846/0449 →
Security Agreement
Feb 8, 2010
From: ESSENTIALIS, INC.
To: STUART COLLINSON, FORWARD VENTURES V, L.P., AS COLLATERAL AGENT
Reel/Frame 023919/0840 →
Assignment of Assignor's Interest
May 17, 2012
From: COWEN, NEIL M.
To: ESSENTIALIS, INC.
Reel/Frame 028228/0586 →
Assignment of Assignor's Interest
Sep 8, 2014
From: COWEN, NEIL M.; PASTERNAK, RICHARD C.
To: ESSENTIALIS, INC.
Reel/Frame 033692/0917 →
Assignment of Assignor's Interest
Feb 13, 2015
From: COWEN, NEIL MADISON
To: ESSENTIALIS, INC.
Reel/Frame 034963/0118 →
Assignment of Assignor's Interest
Nov 13, 2015
From: COWEN, NEIL M
To: ESSENTIALIS, INC.
Reel/Frame 037039/0755 →
Release of Security Interest
Mar 3, 2017
From: ESSENTIALIS, INC.
To: STUART COLLINSON, FORWARD VENTURES V. L. P., AS COLLATERAL AGENT
Reel/Frame 041903/0902 →
Assignment of Assignor's Interest
May 16, 2017
From: COWEN, NEIL M.; KASHKIN, KENNETH B.; YAMOUT, KHALED A.
To: ESSENTIALIS, INC.
Reel/Frame 042470/0234 →
Assignment of Assignor's Interest
May 16, 2017
From: COWEN, NEIL M.; KASHKIN, KENNETH B.; YAMOUT, KHALED A.
To: ESSENTIALIS, INC.
Reel/Frame 042470/0446 →
Assignment of Assignor's Interest
May 16, 2017
From: COWEN, NEIL M.; KASHKIN, KENNETH B.; YAMOUT, KHALED A.
To: ESSENTIALIS, INC.
Reel/Frame 042470/0486 →
Assignment of Assignor's Interest
Aug 8, 2017
From: COWEN, NEIL M.
To: ESSENTIALIS, INC.
Reel/Frame 043235/0059 →
Assignment of Assignor's Interest
Aug 22, 2017
From: KASHKIN, KENNETH B.; COWEN, NEIL MADISON
To: ESSENTIALIS, INC.
Reel/Frame 043359/0927 →
Assignment of Assignor's Interest
Mar 28, 2018
From: KASHKIN, KENNETH B.; COWEN, NEIL MADISON
To: ESSENTIALIS, INC.
Reel/Frame 045371/0979 →
Security Interest
Dec 17, 2024
From: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069613/0369 →
Amended and Restated Intellectual Property Security Agreement
Mar 12, 2025
From: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 070494/0042 →
Release of Security Interest (Reel 070494, Frame 0042)
May 19, 2026
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
Reel/Frame 075601/0687 →
Security Interest
Jun 26, 2026
From: SOLENO THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075106/0487 →